Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a network node, one or more control channel symbols in a subframe. The UE may activate a sleep mode for the subframe irrespective of a control channel decoding result associated with the one or more control channel symbols, wherein the control channel decoding result is associated with a presence or an absence of a downlink shared channel grant. Numerous other aspects are described.

Abstract: A data receiving method, a terminal device, and a system are provided. The terminal device can be connected to an external antenna device, and when the terminal device is connected to the external antenna device, first antennas of the terminal device and second antennas of the external antenna device form a MIMO antenna array. The method includes: acquiring, by the terminal device, first data received by at least one of the first antennas and a composite signal sent by the external antenna device; demultiplexing the composite signal by a demultiplexer to obtain second data corresponding to at least one of the second antennas; and processing the first data and the second data by a processor, so as to obtain target data.

Abstract: A computer server receives, from a remote device, a request for closed caption data, the request specifying media content for which the closed caption data is to be provided. In the server, it is determined whether closed-captioned data for the specified media content is available, and if closed-captioned data for the media content is available, a sequence of records associated with the media content is provided to the device from the server.

Abstract: A computer server receives, from a remote device, a request for closed caption data, the request specifying media content for which the closed caption data is to be provided. In the server, it is determined whether closed-captioned data for the specified media content is available, and if closed-captioned data for the media content is available, a sequence of records associated with the media content is provided to the device from the server.

Abstract: The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are pharmaceutically acceptable salts of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, naphthoic acid derivatives comprising from 11 to 27 carbon atoms, maleic acid and fumaric acid.

Abstract: The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds.

Abstract: There is provided a pharmaceutical composition suitable for topical administration to an eye, the composition comprising as active agent at least one oxazolidinone antibacterial drug, for example linezolid, in a concentration effective for treatment and/or prophylaxis of a gram-positive bacterial infection of an eye, and at least one ophthalmically acceptable excipient ingredient that reduces a rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours. The composition is, for example, an in situ gellable solution, suspension or solution/suspension.

Abstract: There is provided a pharmaceutical composition suitable for topical administration to an eye, the composition comprising as active agent at least one oxazolidinone antibacterial drug, for example linezolid, in a concentration effective for treatment and/or prophylaxis of a gram-positive bacterial infection of an eye, and at least one ophthalmically acceptable excipient ingredient that reduces a rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours. The composition is, for example, an in situ gellable solution, suspension or solution/suspension.

Abstract: An implant composition containing MGA and TBA increases the growth performance, suppresses estrus and prevents pregnancy in heifers. Preferably, the MGA and TBA can be provided in the same, separate or both separate and the same pellets.